Max Robotics — Global Service Robot Directory + US Certification

About

The University of Texas MD Anderson Cancer Center stands as one of the world's premier cancer research and treatment institutions, with a research portfolio that bridges cutting-edge surgical robotics, oncologic outcomes science, and translational medicine. MD Anderson's contributions to robot-assisted and minimally invasive cancer surgery have fundamentally shaped how clinicians approach complex oncologic procedures across multiple tumor sites, from gynecologic and urologic malignancies to head and neck cancers. Among the institution's most impactful contributions is its seminal work on minimally invasive radical hysterectomy for cervical cancer, including a landmark 2018 study that has accumulated nearly 1,900 citations and reshaped international surgical guidelines by rigorously comparing survival outcomes between open and minimally invasive approaches. Equally influential is MD Anderson's pioneering role in transoral robotic surgery (TORS), with multicenter studies establishing safety, feasibility, and oncologic efficacy for oropharyngeal cancers — work that has collectively earned hundreds of citations and directly informed clinical adoption worldwide. The institution has also advanced robotic techniques in thyroid surgery, skull base resection, reconstructive procedures, and radiosurgery quality assurance, demonstrating a remarkably broad technical reach. Foundational contributions to credentialing frameworks for robotic urological surgery further reflect MD Anderson's commitment to responsible technology integration. Complementing its surgical focus, researchers here have produced widely cited guidelines for bladder, colon, and endometrial cancers, alongside impactful work on survivorship issues including sexual dysfunction and infertility following cancer treatment. For prospective collaborators and trainees, MD Anderson represents an unparalleled environment where surgical innovation, rigorous clinical science, and patient-centered outcomes research converge to define the standard of care in oncology.